Catalent enters AAV vector production agreement with IVERIC bio

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/krtiacanut)
(Image: Getty/krtiacanut)

Related tags: Viral vector, Production line, Clinical trial, Trial supply management, Clinical research, Catalent, Catalent pharma solutions

Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.

Iveric bio, which focuses on the development of gene therapy solutions for orphan inherited retinal diseases, will work with Catalent Biologics subsidiary, Paragon Gene Therapy.

Catalent acquired Paragon for $1.2bn in May 2019, for the production of preclinical and clinical trial supply of adeno-associated viral (AAV) vectors.

Together, the companies will produce the AAV vectors needed for Iveric’s drug therapy products IC-100 and IC-200 as they move into the clinic. Clinical trials for IC-100 are expected to begin in 2020 and 2021 for IC-200.

IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for the treatment of BEST1 related retinal diseases, which will be entering Phase I/II clinical trials within the next two years.

A spokesperson for Catalent Biologics told us that through this deal, Iveric bio will have access to Paragon’s manufacturing capabilities and capacity at Catalent’s site in Baltimore, Maryland.

No financial terms have been disclosed.

Related news

Show more

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars